Login to Your Account

Pharma: Clinic Roundup

Friday, August 16, 2013
Boehringer Ingelheim GmbH, of Ingelheim, Germany, said enrollment of more than 950 treatment-naïve genotype-1b patients in the pivotal Phase III interferon-free HCVerso 1 and 2 trials is complete.

To continue reading subscribe now to BioWorld Today

Learn More about BioWorld Today

Already a subscriber? Sign In or Buy now to activate your subscription